Fierce Biotech December 26, 2024
Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies and expansion of site networks, predicts Velocity Clinical Research CEO and President Paul Evans, Ph.D.
Velocity is a clinical research organization headquartered in Durham, North Carolina, with sites across the U.S. and Europe.
In an email to Fierce Biotech, Evans said he expects rising costs to drive efficiency in the industry. Artificial intelligence, he said, could help address rising R&D costs by reducing administrative costs, helping recruit and retain patients and improving data quality.
Several CROs, such as Charles River and Icon, have conducted layoffs amid revenue dips this year caused in part by declining demand from pharmaceutical clients.
Efficiency gains...
Today's Sponsors
Today's Sponsor